Agent Skills
› brycewang-stanford/Awesome-Journal-Skills
› diabetologia
diabetologia
GitHub辅助判断糖尿病研究是否适合投至Diabetologia期刊，涵盖临床、流行病学及基础转化研究。提供选题框架构建、期刊定位对比、报告规范检查及拒稿启发式评估，非临床建议。
Trigger Scenarios
作者将糖尿病临床研究、流行病学或基础/转化研究目标设为Diabetologia并寻求匹配度检查
需根据机制、预防/治疗问题或并发症结果重构糖尿病研究框架
在Diabetologia、JCEM和The Lancet Diabetes & Endocrinology之间选择投稿期刊
需要获取糖尿病研究的报告指南、注册要求及基础/动物实验期望
Install
npx skills add brycewang-stanford/Awesome-Journal-Skills --skill diabetologia -g -y
SKILL.md
Frontmatter
{
"name": "diabetologia",
"description": "Use when targeting Diabetologia or deciding whether a diabetes clinical, epidemiological, or basic\/translational study fits this venue. Encodes the journal's diabetes-focused fit across the evidence spectrum, the mechanistic and methodological bar, reporting-guideline and registration requirements, EASD house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice."
}
Diabetologia (diabetologia)
Journal positioning
Diabetologia is the flagship journal of the European Association for the Study of Diabetes (EASD), publishing diabetes-focused research across the full evidence spectrum — clinical and pragmatic trials, epidemiology and population science, and basic/translational science of islet biology, insulin action, complications, and metabolism. Unlike a broad endocrine journal, Diabetologia is diabetes-dedicated and explicitly welcomes rigorous basic and mechanistic science (beta-cell biology, insulin signaling, animal/cell models) alongside human clinical and epidemiologic work. Its defining expectation is a significant advance in understanding, preventing, treating, or explaining diabetes and its complications, not a small descriptive series or an association study with no mechanistic or clinical payoff. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live Diabetologia author instructions.
When to trigger
- The author names Diabetologia for a diabetes clinical, epidemiological, or basic/translational study and wants a fit/framing check.
- A diabetes study must be re-framed around a mechanism, a prevention/treatment question, or a complications-outcome question.
- The author is choosing between Diabetologia (diabetes-specific, incl. basic science), JCEM (broad endocrine), and The Lancet Diabetes & Endocrinology (high-impact trials).
- The author needs the journal's reporting-guideline, registration, and basic/animal-study expectations for diabetes research.
Scope & topic fit
- Type 1 and type 2 diabetes: pathogenesis, prevention, glucose-lowering therapy, and management trials.
- Diabetes epidemiology and population science: incidence, risk factors, and outcomes across cohorts.
- Islet and beta-cell biology, insulin secretion and action, and metabolic mechanism in cells and animal models.
- Diabetic complications: nephropathy, retinopathy, neuropathy, and cardiovascular disease in diabetes, with mechanism or outcome rigor.
- Gestational diabetes, monogenic diabetes, and metabolic phenotyping studies.
- Diabetes biomarkers, genetics/genomics, and -omics with disease relevance and validation.
Method & evidence bar
- Clinical studies must be adequately powered with prespecified, patient-centered diabetes endpoints; trials require prospective registration and the registration number.
- The applicable reporting guideline and checklist are expected: CONSORT for trials, STROBE for observational/epidemiologic work, PRISMA for systematic reviews, ARRIVE for animal studies.
- Basic/translational work needs rigorous controls, biological replication, validated reagents/models, and blinded/randomized animal experiments where applicable.
- Mechanistic claims require perturbation evidence and, where feasible, anchoring to human islets, tissue, or cohorts; glucose/insulin-clamp and metabolic methods must be described.
- Epidemiologic claims must address confounding, bias, and generalizability; causal language must match the design.
- Effect estimates need confidence intervals and absolute as well as relative measures.
Structure & house style
- EASD/Springer format with a structured abstract (aims/hypothesis, methods, results, conclusions) and a research-in-context/significance statement; re-check current article types and limits on the live guide.
- The introduction frames the diabetes-biology or clinical gap; the discussion states the mechanistic or practice implication and bounds overreach.
- A CONSORT/STROBE/PRISMA flow diagram is expected for the relevant clinical design; animal work reports ARRIVE-aligned detail.
- Figures show representative data with statistics, N, and replication; an electronic supplement carries full methods, the protocol/SAP, and additional experiments.
Official-submission checklist
- Before giving submission-ready advice, read
../../resources/source-basis.mdand../../resources/official-source-map.md; start from the ICMJE/EQUATOR and EASD/Springer anchors, then cite the current Diabetologia page you checked. - Search the live site for "Diabetologia EASD instructions for authors" and follow the current version.
- Re-check article types, abstract structure and research-in-context format, and word/figure/reference limits.
- Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE), data/code-availability, and protocol/SAP submission.
- Re-check IRB/ethics and consent, animal-care/IACUC approval, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure.
- If the live official instructions conflict with this skill, the official instructions win.
Pre-submission self-check
- The study delivers a clear diabetes mechanism, prevention/treatment, or complications advance.
- Clinical diabetes endpoints are prespecified and powered; trials are registered with the number in the manuscript.
- The correct reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE) is completed and attached.
- Basic/translational work shows controls, replication, model validation, and human anchoring.
- Epidemiologic claims address confounding and generalizability; causal language matches the design.
- IRB/consent, IACUC (if animal), ICMJE disclosures, and a data-availability statement are prepared.
Common desk-reject triggers
- Small descriptive diabetes series or registry slice with no mechanism and no clinical payoff.
- Association-only biomarker/-omics studies with no validation cohort or functional follow-up.
- Animal/cell diabetes work without human relevance, replication, or ARRIVE-aligned rigor.
- Missing trial registration, protocol, or the required reporting checklist.
- Broad endocrine scope diluting the diabetes focus, better placed in a generalist endocrine venue.
Re-routing decision
- Broad endocrine (thyroid/adrenal/bone/reproductive) beyond diabetes →
journal-of-clinical-endocrinology-and-metabolism. - High-impact diabetes/endocrine trial with broad reach →
the-lancet-diabetes-and-endocrinology. - Diabetic kidney disease centered on nephrology mechanism/outcomes →
journal-of-the-american-society-of-nephrology/kidney-international. - Obstetric/gestational-diabetes pregnancy outcomes →
american-journal-of-obstetrics-and-gynecology. - Broad practice-changing diabetes trial → general medicine (
jama/ NEJM / The Lancet in the natural-science bundle).
Output format
[Fit] High / Medium / Low (one-line reason)
[Target] Diabetologia (EASD)
[Specialty tags] <T1D / T2D / islet biology / complications / epidemiology + clinical/basic>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / animal-ARRIVE>
[Method/evidence] <power, mechanism, controls/replication, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / IACUC / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>
Version History
- 1839142 Current 2026-07-05 12:35
